molecules

Review
Photodegradation of Anti-Inflammatory Drugs: Stability Tests
and Lipid Nanocarriers for Their Photoprotection
Giuseppina Ioele * , Fedora Grande , Michele De Luca , Maria Antonietta Occhiuzzi, Antonio Garofalo and
Gaetano Ragno

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy;
[email protected] (F.G.); [email protected] (M.D.L.); [email protected] (M.A.O.);
[email protected] (A.G.); [email protected] (G.R.)
* Correspondence: [email protected]; Tel.: +39-0984-493268

Abstract: The present paper provides an updated overview of the methodologies applied in pho-
todegradation studies of non-steroidal anti-inflammatory drugs. Photostability tests, performed
according to international standards, have clearly demonstrated the photolability of many drugs
belonging to this class, observed during the preparation of commercial forms, administration or when
dispersed in the environment. The photodegradation profile of these drugs is usually monitored
by spectrophotometric or chromatographic techniques and in many studies the analytical data are
processed by chemometric procedures. The application of multivariate analysis in the resolution
of often-complex data sets makes it possible to estimate the pure spectra of the species involved in



the degradation process and their concentration profiles. Given the wide use of these drugs, several

 pharmaceutical formulations have been investigated to improve their photostability in solution or
Citation: Ioele, G.; Grande, F.; gel, as well as the pharmacokinetic profile. The use of lipid nanocarriers as liposomes, niosomes or
De Luca, M.; Occhiuzzi, M.A.; solid lipid nanoparticles has demonstrated to both minimize photodegradation and improve the
Garofalo, A.; Ragno, G. controlled release of the entrapped drugs.
Photodegradation of
Anti-Inflammatory Drugs: Stability Keywords: photodegradation; ICH Quality Guidelines; liposomes; niosomes; solid lipid nanoparticles
Tests and Lipid Nanocarriers for
Their Photoprotection. Molecules 2021,
26, 5989. https://doi.org/10.3390/
molecules26195989
1. Introduction
Academic Editor: Brullo Chiara Non-steroidal anti-inflammatory drugs (NSAIDs) represent a class of drugs usually ap-
plied in the treatment of acute or chronic conditions involved in pain and inflammation [1].
Received: 28 August 2021 These analgesic properties have been linked to their inhibitory activity of cyclooxyge-
Accepted: 30 September 2021 nases (COX), presents in two major forms, which convert arachidonic acid into various
Published: 2 October 2021 prostaglandins [2]. Several well-known compounds, such as Ketoprofen, Indomethacin, or
Diclofenac, are active on the constitutive form COX-1, which plays an important role in
Publisher’s Note: MDPI stays neutral cellular homeostasis. Other latest-generation compounds, such as Celecoxib, preferentially
with regard to jurisdictional claims in inhibit the form COX-2 and are highly effective as anti-inflammatory drugs, avoiding the
published maps and institutional affil- adverse gastrointestinal side effects of NSAIDs. However, other studies suggest that pro-
iations. longed use of COX-2 inhibitors may increase the incidence of cardiovascular side effects [3].
Recently, the use of NSAIDs has been safely used to relieve symptoms in patients with
suspicion of Covid-19, and has not been associated with mortality or ventilator care in
these patients [4]. Other pharmacological activities of NSAIDs are well recognized, such as
Copyright: © 2021 by the authors. the inhibitory effect on carcinogenesis and cancer spreading due to different mechanisms,
Licensee MDPI, Basel, Switzerland. including the induction of cell proliferation, apoptosis inhibition, and host’s immune
This article is an open access article response suppression [5].
distributed under the terms and NSAIDs can be classified according to their chemical structure or mechanism of action
conditions of the Creative Commons in: salicylates such as Acetylsalicylic acid; propionic acid derivatives such as Ibuprofen,
Attribution (CC BY) license (https:// Naproxen, Ketoprofen and Flurbiprofen; acetic acid derivatives such as Indomethacin,
creativecommons.org/licenses/by/ Diclofenac and Nabumetone; enolic acid (oxicam) derivatives such as Piroxicam; anthranilic
4.0/).

Molecules 2021, 26, 5989. https://doi.org/10.3390/molecules26195989 https://www.mdpi.com/journal/molecules

Molecules 2021, 26, 5989 2 of 12

acid derivatives (phenamates) such as Mefenamic acid; and selective COX-2 inhibitors
(coxibs) such as Celecoxib [6].
The light sensitivity of these drugs has been studied mainly in commercial formula-
tions [7,8] and in environmental matrices [9–11]. For example, the sunlight exposure of
Diclofenac has been investigated in solution or topical formulations [7], but its photoprod-
ucts are frequently detected in seawater and other aquatic environments [9]. Likewise,
Celecoxib has been detected in river water, in which it is not biologically degraded but
only minimally altered after exposure to sunlight or high temperature [12].
Unfortunately, despite most of the anti-inflammatory drugs for topical use showing
simplicity of application and minimal systemic absorption, adverse cutaneous photosen-
sitivity reactions have been reported [13]. Such photosensitivity reactions are commonly
due to an abnormal light-induced chemical reaction in which the drugs can form various
photoproducts by absorbing radiation. This can cause oxidation of lipids, proteins, and
deoxyribonucleic acid (DNA) and cause phototoxicity with errors during cell replication
and consequently processes of mutagenesis, carcinogenesis, and cell death [14].
The sunlight-guided photocatalytic degradation of harmful drugs and chemicals can
be exploited to eliminate them from the environment [15] or it can be reduced when
it shows signs of danger to the environment or to humans. Several systems have been
proposed to reduce light degradation [16–18]. The first approach in light protection consists
of the use of suitable packaging materials that shield visible and/or UV sun radiation.
Otherwise, the addition of light-absorbent excipients in the formulation is often proposed
to provide the photoprotection of the drugs [7,19,20].
However, the incorporation of drugs into drug delivery systems (DDS) is now the
most successful approach, and is able to reduce light degradation while simultaneously
performing controlled release of drugs. Traditional DDSs have shown significant defi-
ciencies, as they distribute agents non-specifically in the body, thus affecting both targets
and healthy body cells. In contrast, nanoscale DDSs herald innovative nanotechnology
in a wide range of potential therapies, including cancer [21]. Among the most studied
incorporation systems of NSAIDs, vesicular matrices (i.e., liposomes and niosomes) and
solid lipid nanoparticles have shown the best results [22].
Lipid nanosystems offer several advantages, such as the possibility of improving the
stability of the incorporated compounds and allowing their modulated release action. For
example, for drugs, it is possible to improve their solubility in water, their thermal stability,
and increase their oral bioavailability, as well as protecting them during the digestive
process (after oral administration). These systems can also improve their organoleptic
and functional properties [23,24]. Recently, lipid-based nanocarriers were applied for the
encapsulation of essential oils used as “natural food additives” in the preservation process
of food such as cooked rice or rice flour in food industries [25].
This review provides an exhaustive collection of the most widely used approaches in
the investigation of the photodegradation profile of NSAIDs and the lipid delivery devices
proposed for their photoprotection.

2. Photodegradation Studies of NSAIDs

The quality of a drug and of the formulations containing it must be controlled and
ensured during all phases of development. In this quality assurance system, the analytical
methods adopted must be able to reliably measure, in addition to the active compounds,
any degradation products present in the formulation.

2.1. ICH Quality Guidelines

The provisions relating to the methods of determining and applying the stability
studies are provided in the ICH (International Conference on Harmonization) Guideline
to guarantee the safety, efficacy and quality of the tested drugs. These rules describe
the stability tests for the drugs over time in different environmental storage conditions
(pH, temperature, light, air, and humidity) [26]. Among these, the ICH Q1A-R2 test
Molecules 2021, 26, 5989 3 of 12

defines the evaluation of temperature (in 10 ◦ C increments), humidity (e.g., 75% RH or

greater), oxidation, photolysis and hydrolysis over a wide range of pH values in solution
or suspension. The ICH Q1B test includes photostability tests on both pure drug and
its pharmaceutical forms, to verify the light sensitivity even of commercial products in
marketing packages.
The photostability test can be performed by using two different light sources. Accord-
ing to option 1, an artificial daylight fluorescent lamp, combining visible and UV outputs
produces an output similar to the D65/ID65 emission standard. D65 is the internationally
recognized standard for outdoor daylight while ID65 is the equivalent indoor indirect
daylight standard. For a light source emitting significant radiation below 320 nm, an appro-
priate filter may be fitted to eliminate such radiation. Option 2 is performed by combining
a cool white fluorescent with a near ultraviolet lamp (320–400 nm), producing a spectral
distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm
and 370 nm; a significant proportion of UV should be in the two bands 320 to 360 nm and
360 to 400 nm. An appropriate control of the temperature is required in all tests. dedicated
instruments are usually equipped with an electronic device for controlling irradiation
and temperature inside the box. Samples are generally irradiated in a λ range between
300 and 800 nm, by means of selected filters, producing an irradiation power from 250 to
765 W/m2 . The cooling system keeps the temperature constant at 25 ◦ C for radiant power
values higher than 350 W/m2 , while lower radiant power values do not induce an increase
in the temperature inside the irradiation chamber. UV radiation can interact directly with
the drug, causing molecular vibrations that could induce the breaking of bonds with the
formation of free radicals or active species of oxygen, superoxide anions, hydroxyl radicals
or single oxygen and consequently with the formation of photodegradation products [20].
The choice of the parameters in photodegradation experiments, including the type
of radiation and exposure times, are discretionary but should always be justified. To
assess the photodegradation profile of a drug, mild exposure conditions are used, applying
less intense radiation and terminating studies in case of extensive decomposition. In
forced degradation tests, on the other hand, the overall photosensitivity of a drug and the
characterization of any degradation products are evaluated. In these studies, the samples
must be placed in chemically inert and transparent containers and different exposure
conditions can be used, depending on the photosensitivity of the substance involved and
the intensity of the light sources used [26].

2.2. Analytical Techniques for Drug Determination

After optimizing a procedure for the drug recovery from the pharmaceutical or en-
vironmental matrix, it is necessary to establish the analytical method to measure the
amount of the residual drug and its by-products. Considering the characteristics of the
analytes, chromatographic procedures currently represent the most used technique, both
in separation and quantization of the analytes.
In recent years, various chemometric methods, such as Multivariate Curve Resolution
(MCR), have been applied to the data from spectrophotometric or chromatographic meth-
ods. These procedures have made it possible to simultaneously process the data recorded
in multiple experiments and under different experimental conditions, making it possible to
estimate the number of components involved in the full reaction process and the kinetic
photodegradation profile of each component. In particular, the MCR methods make it
possible to decompose an experimental data matrix from a chemical process into the pure
contributions of the single components. The experimental data matrix, D, is decomposed
into the product of two smaller factor matrices, C and ST:

D = C ST + E

where D is the data matrix obtained from the experimental spectral measurements and
contains as many rows as absorption spectra recorded along the chemical process (time,
reaction conditions, etc.), C is the concentration matrix of n components involved in the
Molecules 2021, 26, 5989 4 of 12

process, ST is the spectral matrix of the pure components and E contains the unexplained
data variance [7,16]. In a photodegradation study, the number of species involved is
difficult to determine, and chemical rank analysis can give a lower number of components
than the real number of absorbing species, thus giving a rank deficiency. These problems
could be removed by the simultaneous analysis of multiple experiments, under different
conditions. When a drug is studied in the presence of lipid nanoparticles, MCR is able to
elaborate the spectral data of the matrix components in the modeling step.

2.3. Application of the Photodegradation Test

Many NSAIDs are known to be sensitive to ultraviolet radiations (UVA or UVB)
or visible light. The photodegradation of Acetylsalicylic Acid has been investigated in
different conditions, in the absence or presence of excipients, in the presence of phosphate
buffer (pH equal to 6.4, 7, and 8) or by interaction with NaOH 0.3 M [27]. The intermediate
compounds formed by the process of photocatalytic oxidation or by other mechanisms of
degradation, such as hydrolysis, electrophilic addition, electrons transfer, decarboxylation
reaction, aromatic ring opening, and radical reaction, have been shown to be more toxic
than the pure compound [28,29]. When Paracetamol was exposed to UV irradiation at
254 nm up to 96 h, it degraded by 50% after 24 h, producing a toxic photoproduct, identified
as 1-(2-amino-5-hydroxyphenyl)ethanone. Identification and isolation of this photoproduct
was carried out by HPLC and ESI/TOF/MS/MS. The luminescent bacteria test indicated
that the photoproduct was more toxic than Paracetamol [30]. The photodegradation study
of Ibuprofen was performed by GC-MS. The drug samples in solution were irradiated at
254 nm at a constant temperature of 20 ◦ C for 60 min. The evaluation of the toxicity by Vibrio
fischeri of the photolysis products indicated that this drug generated several photoproducts
more toxic than the base compound [31]. The kinetics of Naproxen photodegradation
was studied in aqueous solutions at 254 nm under de-aerated and aerated conditions, at
pH 7.0 and constant temperature of 25 ◦ C. The formation of two photoproducts, named
1-(6-methoxy-2-naphthyl)ethanol and 2-acetyl-6-methoxy-naphthalene, was evaluated by
HPLC-DAD analysis [32]. Photostability of Diclofenac was investigated in liquid [33] and
gel formulation, showing a clear degradation with the formation of three photoproducts
presenting a quinone imine structure, probably obtained by decarboxylation and oxidation
followed by dehalogenation and cyclization of the drug. In gel formulation, the degradation
process has been monitored by applying the MCR technique to the UV spectral data
from samples exposed to stressing irradiation. In this case, the photodegradation rate of
Diclofenac in gel was very fast, with a residual content of 90% only after 3.90 min under a
radiant exposure of 450 W/m2 at a temperature of 25 ◦ C [7,16].
The stability of Celecoxib was studied by HPLC-DAD by exposing the methanol
solutions, prepared in the range of 0.1–2 µg/mL, to various conditions of forced degra-
dation in the presence of acidic and basic solutions or by exposure to light and heat. The
photochemical profile was verified by exposing the drug to direct sunlight for 30 min,
demonstrating the stability of this compound under these degradation conditions while
the effect of the temperature has been studied by heating the acidic mixture for 30 min at
80 ◦ C, and basic mixture for 10 min at 80 ◦ C [29].
Table 1 summarizes the analytical techniques used in the most widely applied stability
indication methods.

Table 1. Determination methods of anti-inflammatory drugs in pharmaceutical or environmental matrix.

Pharmaceutical Determination
Drug Class Drug References
Formulation Method
Salicylates Aspirin Aqueous solution LC/MS [28]
Solid state FTIR [28]
Aqueous solution GC/MS [27]
Molecules 2021, 26, 5989 5 of 12

Table 1. Cont.

Pharmaceutical Determination
Drug Class Drug References
Formulation Method
Propionic acid derivatives Ibuprofen Aqueous solution GC-MS [31]
Naproxen Aqueous solution HPLC-DAD [32]
Ketoprofen Aqueous solution HPLC-DAD [8]
Aqueous solution HPLC-MS [34]
Acetic acid derivatives Diclofenac Gel formulation UV-Vis/MCR [7,16,33]
Aqueous solution HPLC/MS [33]
Nabumetone Gel formulation UV-Vis and MCR [35]
HPLC
Aniline derivatives Paracetamol Aqueous solution [30]
7/ESI/TOF/MS/MS
Enolic acid derivatives Piroxicam Methanol solution FTIR [36]
Selective COX-2 inhibitors Etoricoxib Aqueous solution UV-Vis [10]
Celecoxib Methanol solution HPLC-DAD [29]

3. Characteristics of Lipid Nanocarriers

The number of studies on nanocarriers in the pharmaceutical field is constantly
growing in terms of disease diagnosis and treatment. Indeed, new formulations of drugs
entrapped in nanocarriers can lead to an improvement in the pharmacokinetic profile of
the drugs and their protection from chemical or physical degradation [37,38].
Various types of nanocarriers are available, based on the different chemical charac-
teristics of the polymers or lipids used for their preparation. Thus, nanocarriers can be
classified as organic-based (as polymeric frameworks, lipid-based frameworks, liposomes
and nanoemulsions), inorganic-based (as metallic nanostructures, silica nanoparticles and
quantum dots), or hybrid combinations of both [37]. The simplest liposomal systems are
composed of natural phospholipids, such as lecithin, which are also the main components
of the biological membranes. These phospholipids can spontaneously self-assemble in
aqueous medium forming one or more compartments in which the drugs are incorpo-
rated. They can act as carriers of hydrophilic (in the aqueous compartments) or lipophilic
molecules (inside the lipid bilayers) [39].
Several lipid nanocarriers are used for the skin delivery of NSAIDs. In the manage-
ment of rheumatoid arthritis, transdermal drug delivery has attracted increasing attention
with respect to the parental route in order to overcome the limitations of systemic side
effects due to the continuous use of corticosteroids [40]. Different nanocarriers have been
applied to enhance the permeation of NSAIDs through the layers of the skin and reach the
site of inflammation, such as liposomes and niosomes.

3.1. NSAIDs in Liposomes

Indomethacin loaded in liposomes exhibited more sustained in vivo anti-inflammatory
effect due to the formation of a drug reservoir in the stratum corneum layer [41]. Due to the
high encapsulation efficiency, these systems guarantee both a sustained release of the drug
and a reduction of the drug content, thus decreasing the potential of unwanted off-target
effects. These matrices are non toxic and allow for targeted administration to inflamed
tissues, as demonstrated for example by the liposomal matrix incorporating Celecoxib [42].

3.2. NSAIDs in Niosomes

Liposomes have some limitations due to the high cost of formulation, lack of stability
at various pH, and limited shelf-life due to the rancidity of the lipids [40]. In recent years,
therefore, new vesicular systems have been studied in which the phospholipid content
of liposomes has been replaced with non-ionic surfactants and cholesterol. Such vesicles,
named niosomes, show better chemical stability, longer shelf-life, and lower cost thanks to
the use of inexpensive non-ionic surfactants. Furthermore, studies carried out on the topical
 therefore, new vesicular systems have been studied in which the phospholipid content of
liposomes has been replaced with non-ionic surfactants and cholesterol. Such vesicles,
Molecules 2021, 26, 5989 named niosomes, show better chemical stability, longer shelf-life, and lower cost thanks
6 of 12
to the use of inexpensive non-ionic surfactants. Furthermore, studies carried out on the
topical treatment of rheumatoid arthritis have shown a better skin penetration of drugs.
For example, Etodolac and Etoricoxib [43] have been incorporated into niosomes in gel
treatment of rheumatoid arthritis have shown a better skin penetration of drugs. For exam-
formulation, while Piroxicam in niosomes [44] has been incorporated into a transdermal
ple, Etodolac and Etoricoxib [43] have been incorporated into niosomes in gel formulation,
patch.
while Piroxicam in niosomes [44] has been incorporated into a transdermal patch.
3.3.
3.3. NSAIDs
NSAIDs in in Solid
Solid Lipid
Lipid Nanoparticles
Nanoparticles
More advanced lipid-based
More advanced lipid-based carrier carrier systems
systemscan canpotentially
potentiallyimprove
improvethe thebioavailability
bioavailabil-
ity of highly hydrophobic, poorly water-soluble and/or lipophilic
of highly hydrophobic, poorly water-soluble and/or lipophilic drugs. In fact, soliddrugs. In fact, solid lipid
lipid
nanoparticles
nanoparticles (SLN) (ranging between 100 and 1000 nm) are colloidal lipid carriers that
(SLN) (ranging between 100 and 1000 nm) are colloidal lipid carriers that
contain
contain solid
solid lipids,
lipids, dispersed
dispersed in in water
water or or in
in an
an aqueous
aqueous surfactant
surfactant solution.
solution. These
These lipids
lipids
are
are prepared
prepared by by using
using fatty
fatty acids,
acids, monoglycerides,
monoglycerides, diglycerides,
diglycerides, triglycerides,
triglycerides, waxes
waxes and
and
steroids, and, depending
steroids, and, dependingon onthe
thepreparation
preparation method,
method, they
they cancan be used
be used for both
for both hydro-
hydrophilic
philic and hydrophobic
and hydrophobic drugs.drugs. In addition,
In addition, to modulate
to modulate drug release,
drug release, such systems
such systems can
can protect
protect the drugs from chemical decomposition [39,45]. Considering
the drugs from chemical decomposition [39,45]. Considering the limited loading capacity the limited loading
capacity
of the drugof the
duedrug
to thedue to the of
presence presence of solid
solid lipids, lipids,
other SLN other
systemsSLN systems
have have been
been developed
developed containing liquid lipids in a solid lipid matrix stabilized with
containing liquid lipids in a solid lipid matrix stabilized with biocompatible emulsifiers, biocompatible
emulsifiers, named nanostructured
named nanostructured lipid carriers lipid carriers
(NLC). The(NLC). The NLC easily
NLC matrices, matrices, easily pro-
produced and
duced
entirelyand entirely
devoid of anydevoid
organic of solvent,
any organic solvent,
are capable are capable oflarge
of encapsulating encapsulating
amount of large
drug,
amount
have good of drug, have storage
long-term good long-term storage
stability and can stability andoral
be used for canadministration
be used for oralofadmin-
poorly
istration of poorly
water-soluble water-soluble and low-bioavailability
and low-bioavailability drugs [45]. Figure 1drugsshows[45].
the Figure
scheme1of shows the
the most
scheme of the most used lipid nanocarriers
used lipid nanocarriers and examples of entrapped NSAIDs.and examples of entrapped NSAIDs.

Figure 1.
Figure Schematic representation
1. Schematic representation of
of liposome,
liposome, niosome
niosome and SLN systems and known examples of
entrapped
of entrapped NSAID
NSAID drugs.
drugs.

Flurbiprofen [46],
Flurbiprofen [46], Ibuprofen
Ibuprofen [47]
[47] and
and Piroxicam
Piroxicam [48]
[48] have
have been
been loaded
loaded in in SLNs
SLNs inin
topical gel
topical gel with
with high
high encapsulation
encapsulationefficiency,
efficiency,demonstrating
demonstratingthat
thatthe concentration
the concentration of of
lipid
li-
andand
pid surfactant plays
surfactant an important
plays rolerole
an important in the entrapment
in the of the
entrapment drugs.
of the In In
drugs. thethe
treatment
treatmentof
ulcerative colitis, a novel biocompatible nanoformulation for Celecoxib has been
of ulcerative colitis, a novel biocompatible nanoformulation for Celecoxib has been devel- developed
with colon
oped specific
with colon characteristic.
specific This NLC
characteristic. This formulation has shown
NLC formulation favorable
has shown characteris-
favorable char-
tics: sustained release of the drug in physiological buffer solution, cytocompatibility for
the normal cells, non-toxicity, safe for enteral human use, and cost-effectiveness [45].

4. Lipid Nanocarriers for Photoprotection of NSAIDs

Drugs are exposed to natural or artificial light throughout their pharmaceutical life,
from their manufacture until dispensation or even after administration. Liquid preparations
are usually less stable than solid formulations for the same drug substances. Several
approaches have been proposed to protect NSAID compounds from light. To realize
Molecules 2021, 26, 5989 7 of 12

light-stable formulations, the use of light-absorbing agents represents one of the most
widely investigated applications. The photoprotective effect of different ultraviolet (UV)
filters has been evaluated with promising results in topical formulations of Ketoprofen, by
adding butyl methoxy dibenzoylmethane [19]. The photostability of Diclofenac has been
greatly increased by adding light absorbers such as octisilate, octyl methoxycinnamate and
a combination of them to the gel formulations [7]. The inhibitory effect of Ascorbic Acid
on Paracetamol, Ibuprofen, and Ketoprofen exposed to UV-B radiation has been studied
with satisfactory results [20]. A clear improvement in the light protection of NSAIDs in
topical formulations has been shown by entrapping the drugs into supramolecular matrices
as cyclodextrins [49,50]. Photoprotection of Diclofenac, Ibuprofen and Naproxen have
been approached through the incorporation of the drugs in several cyclodextrins [7]. Four
photodegradation products were identified after light exposure of Piroxicam in methanol
solution. The inclusion of this drug in 2-hydroxypropyl-cyclodextrin successfully increased
the drug photostability by offering protection from daylight for up to 30 days [36].
Other NSAIDs have been combined in micro- or nanoemulsions to increase light-
stability. Nabumetone and a newly synthesized analog (7-methoxy-2,3-dihydro-1H-cyclope-
nta[b]naphthalene-1-one) have been formulated in microemulsion for topical use to achieve
better photostability and pharmacokinetic profile. Stability tests on both the compounds
have shown a significant increase of photostability in liquid microemulsion and
microemulsion-in-gel, compared to ethanol solution and plain gel. In addition, permeation
experiments on the microemulsion-in-gel formulations have shown a better performance
compared to the plain gel for both the compounds, highlighting the potential of the mi-
croemulsions as delayed drug delivery systems [35]. In developing therapeutic alternatives
for the management of pain and inflammation, Ferreira et al. defined a combination
of pomegranate seed oil and Ketoprofen in nanoemulsions. These nanoemulsions were
demonstrated to be a stable system, presenting advantages over conventional emulsions
due to the smaller droplet size. This also makes it possible to overcome the main limitation
to the long-term therapeutic application of Ketoprofen linked to the harmful effects on the
gastrointestinal tract. This formulation was able to both promote controlled drug release
and drug protection against chemical, enzymatic degradation and photodegradation [51].
Table 2 summarizes all the proposed formulations used in protecting NSAIDs from light.

Table 2. Photo-protective pharmaceutical formulations of anti-inflammatory drugs.

Pharmaceutical
Drug Photo-Protective System References
Formulation
Ibuprofen Aqueous solution Ascorbic acid as UV absorber [20]
Aqueous solution Methyl-β-cyclodextrins [49,50]
Naproxen Aqueous solution Methyl-β-cyclodextrins [49,50]
Methoxy dibenzoylmethane
Ketoprofen Gel [19]
as UV absorber
Aqueous solution Ascorbic acid as UV absorber [20]
Emulsion Nanoemulsion [51]
β-cyclodextrin and
Aqueous solution hydroxypropyl-βcyclodextrin [52]
in liposomes
Bromfenac Aqueous solution Liposomes with chitosan [53]
Octisilate and/or octyl
Diclofenac Gel methoxycinnamate as UV [7]
absorbers
Aqueous solution Methyl-β-cyclodextrins [7,49,50]
Gel Niosomes [16,54]
Niosomes and 5% ascorbic
Gel [16,54]
acid
Nabumetone Gel Microemulsion [35]
Molecules 2021, 26, 5989 8 of 12

Table 2. Cont.

Pharmaceutical
Drug Photo-Protective System References
Formulation
Paracetamol Aqueous solution Ascorbic acid as UV absorber [20]
2-hydroxypropyl-
Piroxicam Aqueous solution [36]
cyclodextrin
Indomethacin Aqueous solution SLNs [55]
Aqueous solution NLCs [55]
Celecoxib Aqueous solution PEGylated liposomes [56]

In the last decade, all the lipid inclusion matrices have also been studied as systems
for preventing the degradation of NSAIDs [24]. These lipid carriers, SLNs in particular,
have gained more importance because of their uniform size, smaller surface area, and high
drug-loading capacity. The stability of a drug has been proved to proportionally increase
with its incorporated quantity and, moreover, the lipid nanoparticles have the ability to
scatter and reflect UV radiation. For these reasons, the application of lipid nanoparticles
in drug formulations could improve the therapeutic efficacy by maintaining a controlled
drug delivery and protecting the drug from degradation.

4.1. Photoprotection of NSAIDs in Liposomes

NSAIDs can form reversible interactions, such as ionic and hydrophobic bonds, with
phospholipids such as phosphatidylcholine [57]. For example, the interactions between
liposomes modified with chitosan, a mucoadhesive cationic polymer, have been studied
to favor the application of Bromfenac on the retina [53]. This formulation has been pre-
pared using the calcium acetate gradient method in which the negatively charged lipid
dicetylphosphate has been incorporated into liposomes, forming an anion layer and pre-
venting coalescence. Drug entrapment efficiency was greater than 90% using this method
when the optimal concentration of chitosan has been selected at 0.15%. A formulation of
Celecoxib entrapped inside the small, lamellar PEGylated liposomes composed of Leciva
S90, cholesterol and methoxy polyethylene glycol di-stearoyl ethanolamine was prepared
by Dave V. et al. through a thin-film hydration method using different molar ratios of
drug to lipid. These liposomes were spherically shaped, with a smoothen surface in the
periphery. The encapsulation efficiency depended on various parameters like the ratio
of lipids and the molar ratio of drug to total lipids. A stability study of the optimized
formulation was performed according to the ICH rules demonstrating the suitable storage
condition at 4 ◦ C. Thus, the use of this entrapping system can offer both efficient release of
Celecoxib and easy administration via the parenteral route, by overcoming the problems
caused by the free drug [56].
Liposomal matrices easily incorporate hydrophilic drugs into the aqueous core and
then release them gently with minimal effect on the stability of the liposome. In contrast,
the incorporation of lipophilic drugs into the lipid bilayer can interfere with the stability of
liposomes [58]. Therefore, drug–cyclodextrin complexes have been developed in recent
years that can make the drug soluble in water which are then loaded into liposomes [59].
This combined approach of cyclodextrin complexation and entrapment in liposomes has
been investigated to develop a topical formulation of Ketoprofen [52]. This drug has been
complexed with β-cyclodextrin and hydroxypropyl-βcyclodextrin using co-evaporation
and sealed-heating methods. Liposomes consisting of phosphatidylcholine and cholesterol
(60%/40%, w/w) have been prepared with different techniques, such as thin layer evap-
oration, freezing and thawing, extrusion through microporous membrane, and reverse
phase evaporation method, obtaining, respectively, multi-lamellar vesicles, frozen and
thawed multi-lamellar vesicles, small uni-lamellar vesicles and large uni-lamellar vesicles.
The prepared complexes have been characterized by differential scanning calorimetry,
Molecules 2021, 26, 5989 9 of 12

demonstrating the influence of the cyclodextrin complex on the size of the liposomes and
not on their lamellar structure.

4.2. Photoprotection of NSAIDs in Niosomes

The new generation of vesicular nanocarriers is represented by niosomes, self-assembled
vesicles composed of non-ionic surfactants with/without adequate amounts of cholesterol
or other amphiphilic molecules. Niosomes have a mono- or multilamellar structure like
liposomes, being able to incorporate both lipophilic and hydrophilic bioactive substances.
However, they have lower production costs and greater stability during storage [60]. Pho-
tostability studies have been performed on topical formulations containing Diclofenac
in niosomal gels and compared to the commercial formulations containing the drug and
standard gels prepared according to the Pharmacopoeia. Niosomal vesicles have been
prepared with Span 60 or Tween 60 as multilamellar systems by adopting lipidic film
method. The photodegradation profiles have been monitored by MCR applied to the
spectral data, allowing to estimate spectra and concentration profiles of parent compound
and by-products. Characterization of niosomes and permeation experiments have also
been carried out to verify the performance of the prepared formulations. Under a radiant
exposure of 450 W/m2 , light stability increased significantly when the drug was entrapped
in niosomal systems in presence of 5% ascorbic acid. Furthermore, the permeation capabil-
ity of Diclofenac has been found to be about three times higher than that measured on the
commercial gel [16,54].

4.3. Photoprotection of NSAIDs in Solid Lipid Nanoparticles

Another alternative to liposomes is represented by SLN and NLC. The latter have
shown greater solubility of the incorporated drugs than SLN. Photostability studies have
demonstrated the efficiency of these vesicular systems in preserving drugs from light
photodegradation [61,62]. For example, Indomethacin has been loaded in SLNs and NLCs
to investigate their potential use in topical ocular delivery. Chitosan (0.1% w/v) has been
incorporated into the aqueous phase prior to preparation of the SLNs for their surface
modification. The proposed formulations increased drug loading capability, entrapment,
and delivery to anterior and posterior segment ocular tissues. Chemical stability has been
investigated in storage conditions, demonstrating that the variation of the lipid compo-
nent in the colloidal framework can improve drug release characteristics and chemical
stability [55].

5. Conclusions
Photodegradation of drugs represents a problem that has emerged in recent decades,
and the definition of photoprotective systems is of fundamental importance in the modern
pharmaceutical industry. Several strategies have been proposed to improve the tendency
of some drugs to degrade when exposed to light. This review reports the main lipid
nanocarrier matrices proposed for drug formulation and their application in ensuring
a valid photoprotection of the incorporated drugs. Lipid nanocarriers are characterized
by the trapping of the drug into a cavity of their structure, involving only weak binding
interactions. They have several advantages as drug carriers, especially for topical adminis-
tration, and have been shown to both improve the pharmacokinetic profile and significantly
increase the light stability of the non-steroidal anti-inflammatory drugs.

Author Contributions: Conceptualization, G.I. and F.G.; methodology, G.I. and M.A.O.; software,
G.I. and M.D.L.; validation, G.I. and A.G.; formal analysis, G.I.; investigation, G.I.; resources, G.I.
and F.G.; data curation, G.I. and M.A.O.; writing—original draft preparation, G.I., M.D.L.; writing—
review and editing, G.I. and G.R.; visualization, G.I. and M.D.L.; supervision, G.I. and G.R.; project
administration, G.I. and A.G.; funding acquisition, G.I. and G.R. All authors have read and agreed to
the published version of the manuscript.
Funding: This research received no external funding.
Molecules 2021, 26, 5989 10 of 12

Acknowledgments: This research was supported by grants from M.U.R.S.T. (Italy).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Day, R.O.; Pinheiro, M.B.; Ferreira, M.L. Non-steroidal anti-inflammatory drugs for
spinal pain: A systematic review and meta-analysis. Ann. Rheum. Dis. 2017, 76, 1269–1278. [CrossRef] [PubMed]
2. Basha, R.; Baker, C.T.; Sankpal, U.T.; Ahmad, S.; Safe, S.; Abbruzzese, J.L.; Abdelrahim, M. Therapeutic applications of NSAIDS in
cancer: Special emphasis on tolfenamic acid. Front. Biosci. 2011, 3, 797–805. [CrossRef]
3. Flattery, M.P.; Hylton Gravatt, L.A. COX-2 inhibitors and cardiovascular risk. Prog. Cardiovasc. Dis. 2005, 20, 123–125. [CrossRef]
[PubMed]
4. Park, J.; Lee, S.H.; You, S.C.; Kim, J.; Yang, K. Non-steroidal anti-inflammatory agent use may not be associated with mortality of
coronavirus disease 19. Sci. Rep. 2021, 11, 5087. [CrossRef]
5. Grande, F.; Giordano, F.; Occhiuzzi, M.A.; Rocca, C.; Ioele, G.; de Luca, M.; Ragno, G.; Panno, M.L.; Rizzuti, B.; Garofalo, A.
Toward multitasking pharmacological cox-targeting agents: Non-steroidal anti-inflammatory prodrugs with antiproliferative
effects. Molecules 2021, 26, 3940. [CrossRef] [PubMed]
6. Kowalski, M.L.; Stevenson, D.D. Classification of reactions to nonsteroidal antiinflammatory drugs. Immunol. Allergy Clin. N. Am.
2013, 33, 135–145. [CrossRef]
7. Ioele, G.; de Luca, M.; Tavano, L.; Ragno, G. The difficulties for a photolabile drug in topical formulations: The case of diclofenac.
Int. J. Pharm. 2014, 465, 284–290. [CrossRef]
8. Takara, A.; Kobayashi, K.; Watanabe, S.; Okuyama, K.; Shimada, Y.; Goto, S. Dibucaine inhibits ketoprofen photodegradation via
a mechanism different from that of antioxidants. J. Photochem. Photobiol. A 2017, 333, 208–212. [CrossRef]
9. Zhang, N.; Li, J.M.; Liu, G.G.; Chen, X.L.; Jiang, K. Photodegradation of diclofenac in seawater by simulated sunlight irradiation:
The comprehensive effect of nitrate, Fe(III) and chloride. Mar. Pollut. Bull. 2017, 117, 366–370. [CrossRef]
10. Cacciari, R.D.; Menis, F.; Biondi, M.A.; Reynoso, E.; Sabini, C.; Montejano, H.A.; Biasutti, M.A. Mechanistic analysis on the
photochemistry of the anti-inflammatory drug etoricoxib in aqueous solution. Cytotoxicity of photoproducts. J. Photochem.
Photobiol. A 2020, 390, 112331. [CrossRef]
11. Tu, N.; Liu, Y.; Li, R.; Lv, W.; Liu, G.; Ma, D. Experimental and theoretical investigation on photodegradation mechanisms of
naproxen and its photoproducts. Chemosphere 2019, 227, 142–150. [CrossRef]
12. Jiménez, J.J.; Pardo, R.; Sánchez, M.I.; Muñoz, B.E. Photochemical, thermal, biological and long-term degradation of celecoxib in
river water. Degradation products and adsorption to sediment. J. Hazard. Mater. 2018, 342, 252–259. [CrossRef]
13. El-Yazbi, A.F.; Guirguis, K.M.; Belal, T.S.; Bedair, M.M. Sensitive spectrofluorimetric and mass spectroscopic methods for the
determination of nucleic acid damage induced by photosensitized anti-inflammatory drugs: Comparative study. J. Pharm. Biomed.
Anal. 2020, 187, 113326. [CrossRef]
14. Zuba, E.B.; Koronowska, S.; Osmola-Mańkowska, A.; Jenerowicz, D. Drug-Induced Photosensitivity. Acta Dermatovenerol. Croat.
2016, 24, 55.
15. Kaur, A.; Umar, A.; Kansal, S.K. Sunlight-Driven Photocatalytic Degradation of Non-Steroidal Anti-Inflammatory Drug Based on
TiO2 Quantum Dots. J. Colloid Interface Sci. 2015, 459, 257–263. [CrossRef] [PubMed]
16. Ioele, G.; Tavano, L.; de Luca, M.; Ragno, G.; Picci, N.; Muzzalupo, R. Photostability and ex-vivo permeation studies on diclofenac
in topical niosomal formulations. Int. J. Pharm. 2015, 494, 490–497. [CrossRef] [PubMed]
17. Nakama, K.A.; dos Santos, R.B.; da Rosa Silva, C.E.; Izoton, J.C.; Savall, A.S.P.; Gutirrez, M.E.Z.; Roman, S.S.; Luchese, C.;
Pinton, S.; Haas, S.E. Establishment of analytical method for quantification of anti-inflammatory agents co-nanoencapsulated
and its application to physicochemical development and characterization of lipid-core nanocapsules. Arab. J. Chem. 2020, 13,
2456–2469. [CrossRef]
18. Ramos, P.T.; Pedra, N.S.; Soares, M.S.P.; da Silveira, E.F.; Oliveira, P.S.; Grecco, F.B.; da Silva, L.M.C.; Ferreira, L.M.; Ribas, D.A.;
Gehrcke, M.; et al. Ketoprofen-Loaded rose hip oil nanocapsules attenuate chronic inflammatory response in a pre-clinical trial in
mice. Mater. Sci. Eng. C 2019, 103, 109742. [CrossRef]
19. Atarashi, K.; Takano, M.; Kato, S.; Kuma, H.; Nakanishi, M.; Tokura, Y. Addition of UVA-absorber butyl methoxy dibenzoyl-
methane to topical ketoprofen formulation reduces ketoprofen-photoallergic reaction. J. Photochem. Photobiol. B 2012, 113, 56–62.
[CrossRef]
20. León, C.; Henríquez, C.; López, N.; Sanchez, G.; Pastén, B.; Baeza, P.; Ojeda, J. Inhibitory effect of the ascorbic acid on
photodegradation of pharmaceuticals compounds exposed to UV-B radiation. J. Photochem. Photobiol. 2021, 7, 314–322. [CrossRef]
21. Iqbal, Z.; Arafa, E.S.A.; Kanwal, Z.; Murtaza, G. Smart solution of severe problems: Radiolabeled nanocarriers for cancer imaging
and therapy. J. Drug Deliv. Sci. Technol. 2021, 61, 102205. [CrossRef]
22. Pimentel-Moral, S.; Teixeira, M.C.; Fernandes, A.R.; Arráez-Román, D.; Martínez-Férez, A.; Segura-Carretero, A.; Souto, E.B. Lipid
nanocarriers for the loading of polyphenols—A comprehensive review. Adv. Colloid Interface Sci. 2018, 260, 85–94. [CrossRef]
23. Severino, P.; Andreani, T.; Macedo, A.S.; Fangueiro, J.F.; Santana, M.H.A.; Silva, A.M.; Souto, E.B. Current state-of-art and new
trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug Deliv. 2012, 2012, 750891. [CrossRef]
24. Ioele, G.; de Luca, M.; Garofalo, A.; Ragno, G. Photosensitive drugs: A Review on their photoprotection by liposomes and
cyclodextrins. Drug Deliv. 2017, 24, 33–44. [CrossRef]
Molecules 2021, 26, 5989 11 of 12

25. Kaliamurthi, S.; Selvaraj, G.; Hou, L.; Li, Z.; Wei, Y.; Gu, K.; Wei, D. Synergism of essential oils with lipid based nanocarriers:
Emerging trends in preservation of grains and related food products. Grain Oil Sci. Technol. 2019, 2, 21–26. [CrossRef]
26. European Medicines Agency. ICH guideline Q1A(R2) ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances
and Products; Current Step 4; European Medicines Agency: Amsterdam, The Netherlands, 2003.
27. Dai, Q.; Xia, Y.; Jiang, L.; Li, W.; Wang, J.; Chen, J. Enhanced degradation of aspirin by electrochemical oxidation with modified
PbO2 electrode and hydrogen peroxide. Int. J. Electrochem. Sci. 2012, 7, 12895–12906.
28. Mukherjee, D.; Ray, A.K.; Barghi, S. Mechanism of acetyl salicylic acid (aspirin) degradation under solar light in presence of a
TiO2 -polymeric film photocatalyst. Processes 2016, 4, 13. [CrossRef]
29. Gugulothu, D.B.; Patravale, V.B. A new stability-indicating HPLC method for simultaneous determination of curcumin and
celecoxib at single wavelength: An application to nanoparticulate formulation. Pharm. Anal. Acta 2012, 3, 157. [CrossRef]
30. Kawabata, K.; Sugihara, K.; Sanoh, S.; Kitamura, S.; Ohta, S. Ultraviolet-photoproduct of acetaminophen: Structure determination
and evaluation of ecotoxicological effect. J. Photochem. Photobiol. A 2012, 249, 29–35. [CrossRef]
31. Iovino, P.; Chianese, S.; Canzano, S.; Prisciandaro, M.; Musmarra, D. Ibuprofen photodegradation in aqueous solutions. Environ.
Sci. Pollut. Res. 2016, 23, 22993–23004. [CrossRef]
32. Marotta, R.; Spasiano, D.; di Somma, I.; Andreozzi, R. Photodegradation of naproxen and its photoproducts in aqueous solution
at 254 Nm: A kinetic investigation. Water Res. 2013, 47, 373–383. [CrossRef]
33. Zhang, N.; Li, J.M.; Liu, G.G.; Chen, X.L.; Jiang, K. Photodegradation of diclofenac in aqueous solution by simulated sunlight
irradiation: Kinetics, thermodynamics and pathways. Water Sci. Technol. 2017, 75, 2163–2170. [CrossRef]
34. Szabó, R.K.; Megyeri, C.S.; Illés, E.; Gajda-Schrantz, K.; Mazellier, P.; Dombi, A. Phototransformation of ibuprofen and ketoprofen
in aqueous solutions. Chemosphere 2011, 84, 1658–1663. [CrossRef]
35. Grande, F.; Ragno, G.; Muzzalupo, R.; Occhiuzzi, M.A.; Mazzotta, E.; de Luca, M.; Garofalo, A.; Ioele, G. Gel formulation of
nabumetone and a newly synthesized analog: Microemulsion as a photoprotective topical delivery system. Pharmaceutics 2020,
12, 423. [CrossRef]
36. Nikolic, V.; Ilic-Stojanovic, S.; Nikolic, L.; Cakic, M.; Zdravkovic, A.; Kapor, A.; Popsavin, M. Photostability of piroxicam in the
inclusion complex with 2-hydroxypropyl-β-cyclodextrin. Hem. Ind. 2014, 68, 107–116. [CrossRef]
37. Mishra, D.K.; Shandilya, R.; Mishra, P.K. Lipid based nanocarriers: A translational perspective. Nanomedicine 2018, 14, 2023–2050.
[CrossRef]
38. Alvarez-Malmagro, J.; Jablonowska, E.; Nazaruk, E.; Szwedziak, P.; Bilewicz, R. How do lipid nanocarriers—Cubosomes affect
electrochemical properties of DMPC bilayers deposited on gold (111) electrodes? Bioelectrochemistry 2020, 134, 103208. [CrossRef]
39. Sala, M.; Diab, R.; Elaissari, A.; Fessi, H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin
interactions and medical applications. Int. J. Pharm. 2018, 535, 1–17. [CrossRef] [PubMed]
40. Anita, C.; Munira, M.; Mural, Q.; Shaily, L. Topical nanocarriers for management of rheumatoid arthritis: A review. Biomed.
Pharmacother. 2021, 141, 111880. [CrossRef] [PubMed]
41. Puglia, C.; Trombetta, D.; Venuti, V.; Saija, A.; Bonina, F. Evaluation of in-vivo topical anti-inflammatory activity of indometacin
from liposomal vesicles. J. Pharm. Pharmacol. 2010, 56, 1225–1232. [CrossRef] [PubMed]
42. Yasmin Begum, M.; Abbulu, K.; Sudhakar, M. Celecoxib loaded liposomes: Development, characterization and in vitro evaluation.
Int. J. Pharm. Sci. Res. 2012, 3, 154.
43. Ravalika, V.; Sailaja, A.K. Formulation and evaluation of etoricoxib niosomes by thin film hydration technique and ether injection
method. Nano Biomed. Eng. 2017, 9, 242–248. [CrossRef]
44. Subashini Rajaram, A.S.; Dharmalingam, S.R.; Chidambaram, K. Fabrication of non-ionic surfactant vesicular gel for effective
treatment of rheumatoid arthritis. J. Evol. Med. Dent. Sci. 2020, 9, 2289–2296. [CrossRef]
45. Mishra, R.K.; Ahmad, A.; Kumar, A.; Vyawahare, A.; Raza, S.S.; Khan, R. Lipid-based nanocarrier-mediated targeted delivery of
celecoxib attenuate severity of ulcerative colitis. Mater. Sci. Eng. C 2020, 116, 111103. [CrossRef]
46. Jain, S.K.; Chourasia, M.K.; Masuriha, R.; Soni, V.; Jain, A.; Jain, N.K.; Gupta, Y. Solid lipid nanoparticles bearing flurbiprofen for
transdermal delivery. Drug Deliv. 2005, 12, 207–215. [CrossRef]
47. Chantaburanan, T.; Teeranachaideekul, V.; Chantasart, D.; Jintapattanakit, A.; Junyaprasert, V.B. Effect of binary solid lipid matrix
of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles
(SLN) for dermal delivery. J. Colloid Interface Sci. 2017, 504, 247–256. [CrossRef]
48. Mohammadi-Samani, S.; Zojaji, S.; Entezar-Almahdi, E. Piroxicam loaded solid lipid nanoparticles for topical delivery: Prepara-
tion, characterization and in vitro permeation assessment. J. Drug Deliv. Sci. Technol. 2018, 47, 427–433. [CrossRef]
49. Ioele, G.; Tavano, L.; Muzzalupo, R.; de Luca, M.; Ragno, G. Stability-indicating methods for nsaids in topical formulations and
photoprotection in host-guest matrices. Mini-Rev. Med. Chem. 2016, 16, 676–682. [CrossRef] [PubMed]
50. Ioele, G.; Tavano, L.; Luca, M.D.; Muzzalupo, R.; Mancuso, A.; Ragno, G. Light-sensitive drugs in topical formulations: Stability
indicating methods and photostabilization strategies. Future Med. Chem. 2017, 9, 1795–1808. [CrossRef] [PubMed]
51. Ferreira, L.M.; Sari, M.H.M.; Cervi, V.F.; Gehrcke, M.; Barbieri, A.V.; Zborowski, V.A.; Beck, R.C.R.; Nogueira, C.W.; Cruz, L.
Pomegranate seed oil nanoemulsions improve the photostability and in vivo antinociceptive effect of a non-steroidal anti-
inflammatory drug. Colloids Surf. B 2016, 144, 214–221. [CrossRef] [PubMed]
52. Maestrelli, F.; González-Rodríguez, M.L.; Rabasco, A.M.; Mura, P. Effect of preparation technique on the properties of liposomes
encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int. J. Pharm. 2006, 312, R713–R715. [CrossRef]
Molecules 2021, 26, 5989 12 of 12

53. Tsukamoto, T.; Hironaka, K.; Fujisawa, T.; Yamaguchi, D.; Tahara, K.; Tozuka, Y.; Takeuchi, H. Preparation of bromfenac-loaded
liposomes modified with chitosan for ophthalmic drug delivery and evaluation of physicochemical properties and drug release
profile. Asian J. Pharm. Sci. 2013, 8, 104–109. [CrossRef]
54. Tavano, L.; de Cindio, B.; Picci, N.; Ioele, G.; Muzzalupo, R. Drug Compartmentalization as strategy to improve the physico-
chemical properties of diclofenac sodium loaded niosomes for topical applications. Biomed. Microdevices 2014, 16, 504–518.
[CrossRef] [PubMed]
55. Balguri, S.P.; Adelli, G.R.; Majumdar, S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for
delivery to the posterior segment ocular tissues. Eur. J. Pharm. Biopharm. 2016, 109, 224–235. [CrossRef] [PubMed]
56. Dave, V.; Gupta, A.; Singh, P.; Gupta, C.; Sadhu, V.; Reddy, K.R. Synthesis and characterization of celecoxib loaded PEGylated
liposome nanoparticles for biomedical applications. Nano Struct. Nano Objects 2019, 18, 100288. [CrossRef]
57. Lichtenberger, L.M.; Zhou, Y.; Jayaraman, V.; Doyen, J.R.; O’Neil, R.G.; Dial, E.J.; Volk, D.E.; Gorenstein, D.G.; Boggara, M.B.;
Krishnamoorti, R. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: Characterization of
interaction of NSAIDs with phosphatidylcholine. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2012, 1821, 994–1002. [CrossRef]
58. Ioele, G.; de Luca, M.; Ragno, G. Photostability of barnidipine in combined cyclodextrin-in-liposome matrices. Future Med. Chem.
2014, 6, 35–43. [CrossRef]
59. Wang, W.X.; Feng, S.S.; Zheng, C.H. A comparison between conventional liposome and drug-cyclodextrin complex in liposome
system. Int. J. Pharm. 2016, 513, 387–392. [CrossRef]
60. Masjedi, M.; Montahaei, T. An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug
delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications. J. Drug Deliv. Sci. Technol. 2021, 61, 102234.
[CrossRef]
61. Puglia, C.; Bonina, F.; Rizza, L.; Blasi, P.; Schoubben, A.; Perrotta, R.; Tarico, M.S.; Damiani, E. Lipid nanoparticles as carrier
for octyl-methoxycinnamate: In vitro percutaneous absorption and photostability studies. J. Pharm. Sci. 2012, 101, 301–311.
[CrossRef]
62. Puglia, C.; Damiani, E.; Offerta, A.; Rizza, L.; Tirendi, G.G.; Tarico, M.S.; Curreri, S.; Bonina, F.; Perrotta, R.E. Evaluation of
nanostructured lipid carriers (NLC) and nanoemulsions as carriers for UV-filters: Characterization, in vitro penetration and
photostability studies. Eur. J. Pharm. Sci. 2014, 51, 211–217. [CrossRef] [PubMed]